News NHS U-turns on Afinitor for TSC-related epilepsy NHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus)
News Novartis hit as Lp(a) drug fails cardio outcomes trial Novartis shares have slipped after it revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
